-
Reed soars to early Masters lead on wings of eagles
-
US Democrats fail in bid to curb Trump's Iran war powers
-
Veteran prop Slimani to return to France with Toulon
-
Iranians pay tribute to slain supreme leader weeks after killing
-
Israel seeks Lebanon talks as its strikes threaten US-Iran truce
-
Russian police raid independent Novaya Gazeta media outlet
-
Barton Snow completes Cheltenham-Aintree double in Foxhunters Chase
-
IMF to cut global growth forecast due to Mideast war
-
Jihadists kill Nigerian troops including senior brigadier general
-
Local boy Aranburu sprints to Basque Country stage, Seixas extends lead
-
Russia brands Nobel Prize-winning rights group Memorial 'extremist'
-
England set for World Cup warm-up friendlies in Florida heat
-
Sabalenka pulls out of Stuttgart Open with injury
-
BTS kick off world tour with spectacular South Korea show
-
UK animal charity rescues over 250 dogs from single home
-
Barton Snow has a lot to crow about in Foxhunters Chase
-
Reigning champion Nick Rockett out of Grand National
-
'Free' McIlroy launches his Masters repeat bid
-
US envoy warns EU won't win AI race 'bringing others down'
-
Trump, Vance not 'meddling' in Hungary vote, says US envoy to EU
-
Jihadists kill 18 Nigerian troops including senior brigadier general
-
Mideast war threatens Africa's supply of humanitarian medicine
-
Seven World Cup winners start for England in Women's Six Nations opener
-
China FM vows deeper ties with North Korea on trip to Pyongyang
-
Sinner survives energy dip, end of streak to see off Machac
-
IMF expects to provide vulnerable economies hit by Iran war up to $50 bn
-
Oil prices jump back toward $100 on Mideast ceasefire doubts
-
Israel vows to fight on as Iran warns ceasefire talks at risk
-
Player tells Tiger to 'get a chauffeur'
-
Believers rejoice as Jerusalem's holy sites re-open
-
EU lawmakers want to tax Big Tech to fund budget
-
Croke Park boss eager to stage Fury-Joshua heavyweight clash in Dublin
-
Cannes Festival promises escapism in Hollywood-lite edition
-
Stabbed for saying no: Is online misogyny fueling violence in Brazil?
-
Israel dismisses calls to add Lebanon to US-Iran ceasefire
-
Russia's Nobel Prize-winning rights group Memorial branded 'extremist'
-
McIlroy ready for early start as 90th Masters begins
-
Fonseca eases into Monte Carlo last eight meeting with Zverev
-
Oil prices jump, stocks drop on Mideast ceasefire doubts
-
Verstappen set for fresh F1 angst as engineer nears Red Bull exit - reports
-
Farhadi, Almodovar, Zvyagintsev to vie for top Cannes Festival prize
-
Ambitious Como's Champions League bid tested by Serie A leaders Inter
-
Emperor penguins listed as endangered species: IUCN
-
Six new caps for France for women's Six Nations opener
-
Calls for US-Iran truce to extend to Lebanon after Israeli strikes
-
Nepal ex-PM Oli gives defiant message after release from custody
-
Despite Middle East truce, airlines fear long-term disruptions
-
Memorial: Russia's Nobel Prize winning rights group facing 'extremism' ban
-
Lebanon mourns dead from Israeli strikes that rattled US-Iran truce
-
Artemis crew's families enthralled by messages from space
Novo Nordisk vows legal action to protect Wegovy pill
Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.
The Danish company only began selling Wegovy in pill form last month after having received approval from the US Food and Drug Administration, but the telehealth company Hims & Hers has begun advertising cheaper versions.
"This is another example of Hims & Hers' historic behaviour of duping the American public with knock-off GLP-1 products," said Novo Nordisk in a statement, referring to the hormone in Wegovy that regulates blood glucose levels and appetite.
"Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework," it added.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Shares in Novo Nordisk have taken a beating this week after it warned of lower sales revenue in the United States as intensified competition pushes down prices.
Y.Zaher--SF-PST